Breast Cancer Study Articles & Analysis: Older
35 news found
Breast cancer remains one of the most challenging diseases to treat, especially for aggressive forms such as triple-negative breast cancer. Researchers are working relentlessly to better understand tumor metabolism and to find new therapeutic strategies. Two recent studies highlight how critical glutamine ...
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and ...
The approval of elacestrant is welcomed as it offers a novel option for patients with ER+, HER2- metastatic breast cancer. This therapy targets the ESR1 mutations in metastatic breast cancer and provides patients with a convenient oral once-daily dose.” “Each year 300,000 Americans are diagnosed with ...
The company presented encouraging results from a clinical study combining samuraciclib with fulvestrant at the 2021 San Antonio Breast Cancer Symposium. ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
There is a strong unmet medical need to provide breast cancer surgeons with specimen imaging tools to aid their decisions ‘real time’ in the operating room. ...
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at ...
Trial start-up activities are already underway, with world-class sites and a number of the nation’s leading breast surgeons identified to participate in Perimeter’s pivotal study, which we anticipate initiating in mid-November at our first site at West Cancer Center’s Breast Center in Germantown, Tennessee under ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that a peer reviewed article titled, “VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot ...
Aurora Technology and Healthcare Global Holdings enters the 2nd most populous continent through a collaboration with the Federal Republic of Nigeria to transform breast cancer care in Africa New York, Abuja, Boston: Representatives of the Nigerian government and Aurora Technology and Healthcare Global Holding Corp. (Aurora) are jointly announcing the signing of a landmark collaboration ...
4D Path, creator of a patented computer-aided pan-cancer diagnostic and precision oncology platform, is pleased to announce that Dr. ...
This study will recruit participants from a territory-wide cancer screening program in Hong Kong who will also undergo breast-dedicated MRI. ...
The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge, a randomized clinical study to evaluate a novel investigational surgical device for the treatment of breast cancer-related lymphedema. This study is sponsored by Fibralign Corporation with funding provided by the National ...
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network (NCCN)ii in its updated guidelines for breast cancer. iii The Oncotype DX ...
Through a prior three-year partnership, 4D Path has already successfully completed three breast cancer clinical studies at Leeds with striking results. Cases from over 1,000 patients from a real-life hospital setting were analyzed across multiple trials using a fully automated 4D workflow. 4D Path, which has raised $6.4 million in funding to ...
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did ...
Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide Exact Sciences Corp. today announced results from three ...
This October Iowa drivers raised over $20,000 for breast cancer research and support services simply by choosing cleaner-burning Unleaded 88 during the 4th annual Pink at the Pump® campaign, co-sponsored by the Iowa Renewable Fuels Association (IRFA) and Iowa Corn Promotion Board (ICPM). Seventy-four retail stations donated three cents of every gallon of Unleaded 88 sold from Oct. 1 through ...
TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium New Publication of Long-term Data from Real-world Clinical Practice Confirms Conclusions of TAILORx Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the ...
Sponsored by the international breast cancer charity, the Know Your Lemons Foundation focuses on breast health education to overcome taboos, fears, and literacy issues. The most famous image of their campaign uses 12 lemons in an egg carton that illustrate 12 signs of breast cancer. The study ...